United Therapeutics Filed Motion In U.S. District Court For The District Of Delaware For Preliminary Injunction In Its Patent Litigation With Liquidia Technologies' Efforts To Seek FDA Approval For PH-ILD For Its Inhaled Treprostinil Product-8K

Author: Benzinga Newsdesk | February 27, 2024 07:18am

Liquidia’s investigational product is currently tentatively approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) but not PH-ILD. In this litigation, the Company alleges that Liquidia’s product for use in pulmonary hypertension associated with interstitial lung disease (PH-ILD) infringes the Company’s U.S. Patent No. 11,826,327 (the ’327 patent), which expires in 2042. The ’327 patent generally covers improving exercise capacity in patients suffering from PH-ILD by administering treprostinil by inhalation. In its preliminary injunction motion, the Company asked the district court to enjoin Liquidia from marketing its product for PH-ILD until the court can adjudicate the Company’s infringement claims.

 

Posted In: LQDA UTHR